biotech and vincent fernando

BNET Resources

• sort by:
• Relevance
• Date
• Popularity

Amylin: A Discounted Option on Byetta's Outcome

Vincent Fernando submits: Amylin AMLN presents a stock opportunity with substantial optionality, and is currently in the sights of activist investor Carl Icahn. I believe Mr. Icahn may not only be trying to make himself a profit, but may also be trying to get Eli Lilly LLY a good...

Tags: Biotech, Healthcare, Vincent Fernando, Amylin Pharmaceuticals Inc., Eli Lilly & Co.

External links 2009-04-22

Amgen Q1 2009 Performance Analysis: Shares Likely Present Compelling Value

Vincent Fernando submits: A concise overview of Amgen's AMGN current situation, post 1Q09 results. Summary Amgen shares trade at a historically cheap trailing PE due to market concerns that key blockbuster drugs are seeing revenue declines and that Amgen’s pipeline is not sufficient to provide...

Tags: Biotech, Vincent Fernando, Amgen Inc.

External links 2009-04-27

Amylin: Icahn's Proxy Damning for Management

Vincent Fernando submits: More on the battle between shareholder activists and biotech company Amylin's AMLN management. Carl Icahn's latest broadside is a set of powerpoint slides, which can be found as a proxy statement with the SEC, which are pretty damning for Amylin management. Amylin management's own...

Tags: Biotech, Vincent Fernando, Amylin Pharmaceuticals Inc., Eli Lilly & Co.

External links 2009-05-10

Key Amylin Catalyst Expected Wednesday

Vincent Fernando submits: A major battle for change at Amylin Pharmaceuticals AMLN could be decided this Wednesday when the company has its annual shareholder meeting and shareholders vote for a potentially new slate of board members put forward by activist shareholders Carl Icahn and Eastbourne Capital. Nevertheless, despite heated...

Tags: Biotech, Vincent Fernando, Amylin Pharmaceuticals Inc.

External links 2009-05-24

Amylin, Biogen Idec Stand to Benefit from Icahn Board Victories

Vincent Fernando submits: Biogen Idec BIIB over-explained its drug development, then called for an extra long recess, in order to delay the shareholder vote whereby activist investor Carl Icahn was trying to repeat his success with Amylin AMLN Pharmaceuticals and add four representatives to Biogen Idec's board. It appears...

Tags: Biotech, Vincent Fernando, Amylin Pharmaceuticals Inc., Biogen Idec Inc.

External links 2009-06-16